VSIR and ovarian cancer: Other studies show that VISTA is overexpressed in tumour tissues, suggesting that it acts as a co-stimulatory molecule inhibiting tumour proliferation and progression—e.g., in ovarian cancer [17], oesophageal adenocarcinoma [18], gastric cancer [19], and hepatocellular carcinoma [20].